Cargando…

Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stability

INTRODUCTION: Recent evidence has shown that the marker of reactive astrogliosis, glial fibrillary acidic protein (GFAP), has a stronger relationship with cerebral amyloid beta (Aβ) pathology in blood than in cerebrospinal fluid (CSF). This study investigates if pre‐analytical treatment of blood and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simrén, Joel, Weninger, Haley, Brum, Wagner S., Khalil, Shilla, Benedet, Andréa L., Blennow, Kaj, Zetterberg, Henrik, Ashton, Nicholas J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826213/ https://www.ncbi.nlm.nih.gov/pubmed/36102852 http://dx.doi.org/10.1002/alz.12806

Ejemplares similares

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
por: Benedet, Andréa L., et al.
Publicado: (2021)

Comparing Glial Fibrillary Acidic Protein (GFAP) in Serum and Plasma Following Mild Traumatic Brain Injury in Older Adults
por: Huebschmann, Nathan A., et al.
Publicado: (2020)

Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre‐analytical conditions
por: Simrén, Joel, et al.
Publicado: (2021)

Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis
por: Martínez, M Alba Mañé, et al.
Publicado: (2015)

Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy
por: Freigang, Maren, et al.
Publicado: (2022)

Serum Neurofilament Light, Glial Fibrillary Acidic Protein and Tau Are Possible Serum Biomarkers for Activity of Brain Metastases and Gliomas
por: Hepner, Adriana, et al.
Publicado: (2019)

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection
por: Hermansson, Linn, et al.
Publicado: (2019)

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
por: Cicognola, Claudia, et al.
Publicado: (2021)

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples
por: Skillbäck, Tobias, et al.
Publicado: (2013)

Extracellular fluid, cerebrospinal fluid and plasma biomarkers of axonal and neuronal injury following intracerebral hemorrhage
por: Tobieson, Lovisa, et al.
Publicado: (2021)

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS
por: Hölttä, Mikko, et al.
Publicado: (2012)

Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease
por: Hall, Sara, et al.
Publicado: (2016)

Effects of pre‐analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration
por: Ashton, Nicholas J., et al.
Publicado: (2021)

The accuracy and robustness of plasma biomarker models for amyloid PET positivity
por: Benedet, Andréa L., et al.
Publicado: (2022)

Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease
por: Erickson, Pontus, et al.
Publicado: (2023)

The Relationships between Cerebrospinal Fluid Glial (CXCL12, CX3CL, YKL-40) and Synaptic Biomarkers (Ng, NPTXR) in Early Alzheimer’s Disease
por: Kulczyńska-Przybik, Agnieszka, et al.
Publicado: (2023)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
por: Nilsson, Johanna, et al.
Publicado: (2021)

Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease
por: Chatterjee, Pratishtha, et al.
Publicado: (2021)

Molecular forms of neurogranin in cerebrospinal fluid
por: Nazir, Faisal Hayat, et al.
Publicado: (2020)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer’s Disease: A Pilot Study
por: Thordardottir, Steinunn, et al.
Publicado: (2020)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
por: Sjödin, Simon, et al.
Publicado: (2017)

Growth differentiation factor 15 increases in both cerebrospinal fluid and serum during pregnancy
por: Andersson-Hall, Ulrika, et al.
Publicado: (2021)

Changes in serum and cerebrospinal fluid cytokines in response to non-neurological surgery: an observational study
por: Bromander, Sara, et al.
Publicado: (2012)

Cerebrospinal fluid biomarkers of axonal and synaptic degeneration in a population-based sample
por: Arvidsson Rådestig, Maya, et al.
Publicado: (2023)

Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus
por: Tyrberg, Tobias, et al.
Publicado: (2020)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid
por: Selnes, Per, et al.
Publicado: (2010)

Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection
por: Bremell, Daniel, et al.
Publicado: (2013)

Cerebrospinal fluid monoamine metabolite profiles in bipolar disorder, ADHD, and controls
por: Pålsson, Erik, et al.
Publicado: (2017)

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
por: Bjerke, Maria, et al.
Publicado: (2010)

Cognitive Performance and Cerebrospinal Fluid Biomarkers of Neurodegeneration: A Study of Patients with Bipolar Disorder and Healthy Controls
por: Rolstad, Sindre, et al.
Publicado: (2015)

Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays
por: Öhrfelt, Annika, et al.
Publicado: (2020)

Cerebrospinal fluid microglia and neurodegenerative markers in twins concordant and discordant for psychotic disorders
por: Johansson, Viktoria, et al.
Publicado: (2016)

Cognitive impairment without altered levels of cerebrospinal fluid biomarkers in patients with encephalitis caused by varicella-zoster virus: a pilot study
por: Eckerström, Marie, et al.
Publicado: (2020)

Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease
por: Niemelä, Valter, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rmcur1g0kdgv0a5o1dd7514lou